NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Earnings for NRx Pharmaceuticals, Inc. (NRXP)
Earnings in 2023 (TTM): $-30,159,000
According to NRx Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-30,159,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of NRx Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-30,159,000 | $-30,150,000 |
| 2022 | $-39,816,000 | $-35,235,000 |
| 2021 | $-93,063,000 | $-71,715,000 |
| 2020 | $-51,777,000 | $-12,347,000 |
| 2019 | $492.63 K | $408.43 K |
| 2018 | $82.41 K | $66.1 K |
| 2017 | $-105,033 | $-105,033 |